Atorvastatin influence on glycemic control in patients with type 2 diabetes mellitus

Farmacia

Volumn 58, Issue 6, 2010, Pages 728-734

  Ionicǎ, Floriana Elvira ^a   Pisoschi, Cǎtǎlina ^a   Negreş, Simona ^b   Nikos, Rigas F ^a   Tǎrâţǎ, Mihai ^a   Popescu, Florica ^a  

^a UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Atorvastatin; Glycemia; Type 2 diabetes mellitus

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; GLIBENCLAMIDE; GLIMEPIRIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DIABETIC PATIENT; DISEASE PREDISPOSITION; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK REDUCTION; TREATMENT OUTCOME;

EID: 78650703261     PISSN: 00148237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Haffner S.M., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. - Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998, 339, 229-234.
2. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., Simes R. Cholesterol Treatment Trialists' (CTT) collaborators - Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet, 2005, 366, 1267-1278.
3. Arca M. - Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs, 2007, 67, Suppl.1, 43-54.
4. Costa J., Borges M., David C., Vaz Carneiro A. - Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomized controlled trials. BMJ, 2006, 332, 1115-1124.
5. Kamari Y., Bitzur R., Cohen H., Shaish A., Harats D. - Should all diabetic patients be treated with a statin? Diabetes Care, 2009, 32 Suppl.2, S379-S383
6. Suciu M. - The role of nitric oxide (NO) and statins in endothelial dysfunction and atherosclerosis. Farmacia, 2009, 2, 131-140.
7. th edition in Romanian language, Vol. 1, 1481-1483.
8. Horvath E.M., Tackett L., Elmendorf J.S. - A novel membrane-based anti-diabetic action of atorvastatin. Biochem Biophys Res Commun, 2008, 372 (4), 639-643.
9. Koha K.K., Quonb M.J., Hana S.H., Leec Y., Kima S.J., Parka J.B., Shina E.K. - Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis, 2009, 204, 483-490.
10. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., Braunwald E. for the Cholesterol and Recurrent Events (CARE) Investigators - Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation, 1998, 98, 839-844.
11. Baker W.L., Talati R., White C.M., Coleman C.I. - Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis. Diabetes Research and Clinical Practice 2010, 87, 98-107.